Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
Full Year Results 2024
Watch Riad Mishlawi, CEO
Latest stories
Featured
Hikma to host meet the management and site visit in Columbus, Ohio
Press Release, Corporate
17 March 2025
- Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA Press Release, Business Development 09 April 2025 Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA
- Hikma launches Cisatracurium Besylate Injection, USP in the US Press Release, Product 25 March 2025 Hikma launches Cisatracurium Besylate Injection, USP in the US
- Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg Press Release, Product 20 March 2025 Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
- Developing our pipeline in growing therapeutic areas Story, Corporate 19 March 2025 Developing our pipeline in growing therapeutic areas
